Connecting You to Tomorrow's Biotechnology Innovations
Eureka Therapeutics, a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, announced preliminary safety and clinical results from its ongoing proof-of-concept study of ET140202 T-cell therapy in AFP-positive patients with hepatocellular carcinoma (HCC), the most prevalent form of liver […]
A research team led by scientists from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC) or primary liver cancer. This landmark discovery opens door for more effective treatment of liver cancer […]
A group of researchers from Mayo Clinic and Exact Sciences Corporation have completed a phase II study comparing a set of DNA markers to alpha fetoprotein as a method to test for liver cancer. The researchers presented their findings today at the 2018 Digestive Disease Week conference in Washington, D.C. “We currently test for liver cancer using ultrasound and a blood […]
Indiana University researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver failure and liver cancer. It’s estimated that 2 billion people worldwide have had a hepatitis B virus infection in their lifetime, with about 250 million — including 2 million Americans — […]
According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. The research was conducted over more than two years by Pluristem Therapeutics, Inc., a Haifa-based biotechnology company. The article titled “Human Placental-Derived Adherent […]
Penn study shows patients can benefit from fewer side effects and lower treatment costs Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to […]
Namodenoson, a Phase II drug developed by Can-Fite BioPharma Ltd. (NYSE MKT: CANF), has shown in newly published data that it prevents liver (hepatic) fibrosis progression in preclinical studies. “These latest study results add to the growing body of data that demonstrate Namodenoson’s potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to […]
Q BioMed, Inc., a New York City-based biomedical acceleration and development company has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent […]
Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in […]